Barinthus Biotherapeutics
BRNS
14 hedge funds and large institutions have $9.02M invested in Barinthus Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.5% less ownership
Funds ownership: 23.58% → 23.08% (-0.5%)
1% less capital invested
Capital invested by funds: $9.15M → $9.02M (-$127K)
7% less funds holding
Funds holding: 15 → 14 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$87.4K |
| 2 |
Morgan Stanley
New York
|
+$3.48K |
| 3 |
Renaissance Technologies
New York
|
+$524 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gilead Sciences
Foster City,
California
|
-$236K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MGP
1
M&G plc
London,
United Kingdom
| $5.2M | – | – | – |
|
|
AI
2
Alphabet Inc
Mountain View,
California
| $1.41M | – | – | – |
|
|
HH
3
HSG Holding
Na,
Hong Kong
| $1.32M | – | – | – |
|
|
DF
4
DC Funds
Mclean,
Virginia
| $597K | – | – | – |
|
|
5
Baird Financial Group
Milwaukee,
Wisconsin
| $179K | +$87.4K | +100,000 | +108% |
|
|
JHU
6
Johns Hopkins University
Baltimore,
Maryland
| $114K | – | – | – |
|
|
GS
7
Gilead Sciences
Foster City,
California
| $92.5K | -$236K | -270,377 | -73% |
|
8
HighTower Advisors
Chicago,
Illinois
| $34.8K | – | – | – |
|
|
9
Renaissance Technologies
New York
| $33.8K | +$524 | +600 | +2% |
|
|
10
Citadel Advisors
Miami,
Florida
| $14.8K | -$8.69K | -9,945 | -38% |
|
11
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| $14K | – | – | – |
|
12
Geode Capital Management
Boston,
Massachusetts
| $10.5K | – | – | – |
|
|
13
Morgan Stanley
New York
| $4.51K | +$3.48K | +3,981 | +457% |
|
|
NECFA
14
New England Capital Financial Advisors
Meriden,
Connecticut
| $42 | – | – | – |
|
BRNS Hedge Fund Activity: Q2 2025 in Review
14 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q2 2025, worth a combined $9.02M — down 1.4% from $9.15M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BRNS and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Baird Financial Group, adding an estimated $87.4K. The largest seller was Gilead Sciences, cutting an estimated $236K.
- 14 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q2 2025, down from 15 in Q1 2025.
- Funds reported $9.02M of Barinthus Biotherapeutics stock for Q2 2025, down 1.4% quarter-over-quarter.
- 0 funds opened new Barinthus Biotherapeutics positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest Barinthus Biotherapeutics buyer in Q2 2025 was Baird Financial Group, an estimated $87.4K added.
- The largest Barinthus Biotherapeutics seller in Q2 2025 was Gilead Sciences, an estimated $236K sold.
Based on aggregated 13F filings for Q2 2025.